Compare Amphastar Pharmaceuticals Inc (AMPH) vs Cenovus Energy Inc (CVE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Cenovus Energy Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.74 (market cap $826.08M), while Cenovus Energy Inc trades at $26.81 (market cap $49.07B). The key difference: Cenovus Energy Inc is far larger — about 59.4× Amphastar Pharmaceuticals Inc's market cap, and Cenovus Energy Inc pays a 2.35% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | CVE | |
|---|---|---|
Market Cap | $826.08M | $49.07B |
Sector | Health | Energy |
52-Week High | $30.81 | $31.80 |
52-Week Low | $16.87 | $13.96 |
Enterprise Value | $1.22B | $56.95B |
Dividend Yield | — | 2.35% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Cenovus Energy (CVE) trades at $26.40, up 1.62% today, with a bullish technical signal from moving averages. The stock shows strong fundamentals with a P/E of 14.93 and net income margin of 8.94%, supported by three consecutive quarterly earnings beats. Recent news highlights its 85% annual rally, driven by oil price gains and operational synergies from MEG Energy.
The outlook remains positive given its low-cost assets and integrated model, though risks include oil price volatility and execution of growth plans. Analyst consensus is mixed with 40.7% buy ratings, reflecting cautious optimism amid energy sector momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Cenovus Energy Inc
Cenovus Energy is an integrated oil company, focused on creating value through the development of its oil sands assets. The company also engages in production of conventional crude oil, natural gas liquids, and natural gas in Alberta, Canada, with refining operations in the U.S. Net upstream production averaged 472 thousand barrels of oil equivalent per day in 2020, and the company estimates that it holds 6.7 billion boe of proven and probable reserves.
Read more on CVE →
